# NIKTIMVO (axatilimab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/axatilimab

> The FDA approved NIKTIMVO (axatilimab), sponsored by INCYTE CORP (INCY), on Jan 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | NIKTIMVO (axatilimab) |
| Codes | SNDX6352, INCA034176, SNDX-6352 |
| Sponsor | INCYTE CORP (INCY) https://sec-api.dev/companies/incy/catalysts |
| Indications | [idiopathic pulmonary fibrosis](https://sec-api.dev/indications/idiopathic-pulmonary-fibrosis), newly diagnosed chronic gvhd, [chronic graft-versus-host disease, or cgvhd](https://sec-api.dev/indications/chronic-graft-versus-host-disease-or-cgvhd), [Chronic Graft-versus-host-disease](https://sec-api.dev/indications/chronic-graft-versus-host-disease) |
| Modality | antibody |
| FDA designations | priority review |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month. Indication: chronic graft-versus-host disease, or cGVHD.
- First seen 2025-03-03, last confirmed 2025-03-03.
- SEC Form 10-K (accession 0000950170-25-030394): "Niktimvo (axatilimab-csfr) is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030394/sndx-20241231.htm

### Jan 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-02-10, last confirmed 2025-02-10.
- Press release filed with the SEC (EX-99) (accession 0001628280-25-004514): "•In January 2025, Incyte and Syndax Pharmaceuticals announced that the FDA approved Niktimvo™ (axatilimab-csfr) in 9 mg and 22 mg vial sizes." https://www.sec.gov/Archives/edgar/data/879169/000162828025004514/incy-q42024xexx991.htm

### October 25, 2025: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2025-08-04, last confirmed 2025-08-04.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101974): "- sNDA in R/R mNPM1 AML granted Priority Review; PDUFA action date of October 25, 2025 -" https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101974): "The sNDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "The sNDA is being reviewed under the FDA's Real-Time Oncology Review program and has been assigned a PDUFA target action date of October 25, 2025." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm

### August 27, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Idiopathic Pulmonary Fibrosis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06132256 (MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Syndax Pharmaceuticals." https://clinicaltrials.gov/study/NCT06132256

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: newly diagnosed chronic GVHD.
- First seen 2025-03-03, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0000879169-26-000053): "•Topline data from the Phase 2 trial evaluating axatilimab in combination with ruxolitinib in patients with newly diagnosed chronic GVHD are anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/879169/000087916926000053/incy-q22026xexx991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197124): "The Company expects to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-076522): "The Company expects to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076522/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-262509): "The Company expects to complete enrollment in the trial by the end of 2025 with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262509/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-101974): "The Company expects to complete enrollment in the trial in the fourth quarter of 2025 with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101974/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063514): "The Company expects to complete enrollment in the trial in 2025 with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000095017025063514/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030392): "The company expects to complete enrollment in the trial in 2025 with topline data anticipated in 2026." https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-197154): "We expect to report topline data in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312526197154/sndx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-076536): "We expect to report topline data from the trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-262521): "The Company expects to complete enrollment in the trial by the end of 2025 with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000119312525262521/sndx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-101985): "The Company expects to complete enrollment in the trial in the fourth quarter of 2025 with topline data anticipated in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1395937/000095017025101985/sndx-20250630.htm
- ClinicalTrials.gov: "NCT06132256 (MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-27 (ACTUAL); Lead Sponsor Syndax Pharmaceuticals." https://clinicaltrials.gov/study/NCT06132256

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-02, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-443613): "The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443625): "The Company expects topline data from the Phase 2 trial of axatilimab in combination with ruxolitinib to be presented at a medical meeting in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06585774

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06585774 (A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06585774

### early 2028: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2026-02-26, last confirmed 2026-11-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-443613): "The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443613/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-443625): "The Company expects topline data from the Phase 3 trial of axatilimab in combination with corticosteroids in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526443625/sndx-20260930.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-332736): "Topline data are anticipated in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526332736/sndx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-197124): "Topline data is anticipated in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526197124/sndx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-332750): "We anticipate topline data in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526332750/sndx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-197154): "Topline data is anticipated in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526197154/sndx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-076536): "Topline data from the trial is anticipated in early 2028." https://www.sec.gov/Archives/edgar/data/1395937/000119312526076536/sndx-20251231.htm

### May to Aug 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06821542

### May 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06821542 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT06821542

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT07124078

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Graft-versus-host-disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07124078 (A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-31 (ESTIMATED); Lead Sponsor Incyte Corporation." https://clinicaltrials.gov/study/NCT07124078

## Same indication

- [LTI-03](https://sec-api.dev/pdufa/lti-03) (RNTX)
- [LTSE-2578](https://sec-api.dev/pdufa/ltse-2578) (GPCR)
- [Ofev® (nintedanib)](https://sec-api.dev/pdufa/nintedanib) (AVLN)
- [Revuforj® (revumenib)](https://sec-api.dev/pdufa/revumenib) (SNDX)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [TTI-101](https://sec-api.dev/pdufa/tti-101) (TVRD)

Calendar months: [October 2025](https://sec-api.dev/fda-calendar/2025-10), [September 2027](https://sec-api.dev/fda-calendar/2027-09), [May 2028](https://sec-api.dev/fda-calendar/2028-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/axatilimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NIKTIMVO (axatilimab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/axatilimab

```bibtex
@misc{secapidev_pdufa_axatilimab_20261116,
  title        = {NIKTIMVO (axatilimab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/axatilimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_axatilimab_20261116","title":"NIKTIMVO (axatilimab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/axatilimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
